Assertio Holdings Announces April 29 Tender Offer Commencement for Garda Therapeutics Acquisition
Summary
Assertio Holdings announced that Garda Therapeutics intends to commence its tender offer to acquire all outstanding shares on April 29, 2026, following the expiration of the 'window-shop' period.
Key Events
-
Tender Offer Commencement Date Set
Garda Therapeutics, Inc. intends to commence the tender offer to acquire all outstanding shares of Assertio Holdings, Inc. on April 29, 2026.
-
Follows Window-Shop Period
The tender offer will begin the day following the expiration of the 20-day 'window-shop' period contemplated by the definitive merger agreement.
-
Acquisition Context
This update relates to the definitive agreement announced on April 8, 2026, for Garda Therapeutics to acquire Assertio for $18.00 per share in cash, plus a contingent value right.
Analysis
This 8-K provides a critical timeline update for the previously announced acquisition of Assertio Holdings by Garda Therapeutics. By confirming the tender offer commencement date of April 29, 2026, it reduces uncertainty surrounding the deal's progression and signals that the acquisition is moving forward as planned following the expiration of the 'window-shop' period. This is a significant step towards the completion of the merger, which was initially announced on April 8, 2026.
At the time of this filing, ASRT was trading at $18.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.1M. The 52-week trading range was $8.55 to $20.45. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.